Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Ronkainen, Hanna ^a   Kauppila, Saila ^a   Hirvikoski, Pasi ^a   Vaarala, Markku H ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MYOSIN VI; UVOMORULIN; CADHERIN; MYOSIN HEAVY CHAIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; EVALUATION; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MYOSIN HEAVY CHAINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649300204     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-2     Document Type: Article

References (32)

1. The changing natural history of renal cell carcinoma. AJ Pantuck A Zisman AS Belldegrun, J Urol 2001 166 1611 1623 10.1016/S0022-5347(05)65640-6 11586189
2. Prognostic factors and molecular markers for renal cell carcinoma. MH Bui A Zisman AJ Pantuck KR Han J Wieder AS Belldegrun, Expert Rev Anticancer Ther 2001 1 565 575 10.1586/14737140.1.4.565 12113089
3. Myosin VI is an actin-based motor that moves backwards. AL Wells AW Lin LQ Chen D Safer SM Cain T Hasson BO Carragher RA Milligan HL Sweeney, Nature 1999 401 505 508 10.1038/46835 10519557
4. Identification of myosin in human epithelial cancers with immunofluorescence. JC Macartney MA Trevithick L Kricka RC Curran, Lab Invest 1979 41 437 445 388073
5. How are the cellular functions of myosin VI regulated within the cell? F Buss J Kendrick-Jones, Biochem Biophys Res Commun 2008 369 165 175 10.1016/j.bbrc.2007.11.150 18068125
6. What can myosin VI do in cells? HL Sweeney A Houdusse, Curr Opin Cell Biol 2007 19 57 66 10.1016/j.ceb.2006.12.005 17175153
7. Myosin VI is required for E-cadherin-mediated border cell migration. ER Geisbrecht DJ Montell, Nat Cell Biol 2002 4 616 620 12134162
8. Mechanisms of tumour metastasis. T Meyer IR Hart, Eur J Cancer 1998 34 214 221 10.1016/S0959-8049(97)10129-0 9741324
9. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. M Takeichi, Development 1988 102 639 655 3048970
10. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. CL Sommers EW Thompson JA Torri R Kemler EP Gelmann SW Byers, Cell Growth Differ 1991 2 365 372 1793731
11. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Y Doki H Shiozaki H Tahara M Inoue H Oka K Iihara T Kadowaki M Takeichi T Mori, Cancer Res 1993 53 3421 3426 8324752
12. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. R Umbas WB Isaacs PP Bringuier HE Schaafsma HF Karthaus GO Oosterhof FM Debruyne JA Schalken, Cancer Res 1994 54 3929 3933 7518346
13. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. PP Bringuier R Umbas HE Schaafsma HF Karthaus FM Debruyne JA Schalken, Cancer Res 1993 53 3241 3245 8324734
14. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. S Dorudi JP Sheffield R Poulsom JM Northover IR Hart, Am J Pathol 1993 142 981 986 7682766
15. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. ML Gervais PC Henry A Saravanan TN Burry BL Gallie MA Jewett RP Hill AJ Evans M Ohh, Lab Invest 2007 87 1252 1264 10.1038/labinvest.3700684 17906660
16. Functional interaction of beta-catenin with the transcription factor LEF-1. J Behrens JP von Kries M Kuhl L Bruhn D Wedlich R Grosschedl W Birchmeier, Nature 1996 382 638 642 10.1038/382638a0 8757136
17. The significance of the Wnt pathway in the pathology of human cancers. R Karim G Tse T Putti R Scolyer S Lee, Pathology 2004 36 120 128 10.1080/00313020410001671957 15203747
18. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma. H Ronkainen MH Vaarala S Kauppila Y Soini TK Paavonen J Rask P Hirvikoski, Oncol Rep 2009 21 1519 1523 19424632
19. TNM Classification of Malignant Tumours. UICC, Wiley & Sons, New York 6 2002
20. Tumours of the Urinary System and Male Genital Organs. IARC, IARC Press, Lyon 2004
21. A novel role of myosin VI in human prostate cancer. TA Dunn S Chen DA Faith JL Hicks EA Platz Y Chen CM Ewing J Sauvageot WB Isaacs AM De Marzo J Luo, Am J Pathol 2006 169 1843 1854 10.2353/ajpath.2006.060316 17071605
22. Myosin VI is a modulator of androgen-dependent gene expression. I Loikkanen K Toljamo P Hirvikoski T Vaisanen TK Paavonen MH Vaarala, Oncol Rep 2009 22 991 995 19787211
23. The temporal and spatial expression pattern of myosin Va, Vb and VI in the mouse ovary. L McGurk G Tzolovsky N Spears M Bownes, Gene Expr Patterns 2006 6 900 907 10.1016/j.modgep.2006.03.002 16713372
24. Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. H Yoshida W Cheng J Hung D Montell E Geisbrecht D Rosen J Liu H Naora, Proc Natl Acad Sci USA 2004 101 8144 8149 10.1073/pnas.0400400101 15146066
25. The complementary role of beta-catenin in diagnosing various subtypes of renal cell carcinomas and its up-regulation in conventional renal cell carcinomas with high nuclear grades. L Guo N Kuroda E Miyazaki Y Hayashi M Toi K Naruse M Hiroi S Ashida T Shuin H Enzan, Oncol Rep 2001 8 521 526 11295073
26. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. AJ Evans RC Russell O Roche TN Burry JE Fish VW Chow WY Kim A Saravanan MA Maynard ML Gervais RI Sufan AM Roberts LA Wilson M Betten C Vandewalle G Berx PA Marsden MS Irwin BT Teh MA Jewett M Ohh, Mol Cell Biol 2007 27 157 169 10.1128/MCB.00892-06 17060462
27. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. M Iwamoto DJ Ahnen WA Franklin TH Maltzman, Carcinogenesis 2000 21 1935 1940 10.1093/carcin/21.11.1935 11062151
28. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. YS Bian MC Osterheld FT Bosman C Fontolliet J Benhattar, Am J Clin Pathol 2000 114 583 590 10.1309/3QLC-5MF1- JYXU-A5XX 11026105
29. Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. A Ougolkov M Mai Y Takahashi K Omote V Bilim A Shimizu T Minamoto, J Exp Clin Cancer Res 2000 19 349 355 11144528
30. beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. M Saegusa M Hashimura T Yoshida I Okayasu, Br J Cancer 2001 84 209 217 10.1054/bjoc.2000.1581 11161379
31. Nuclear localization of E-cadherin expression in Merkel cell carcinoma. AC Han AP Soler CK Tang KA Knudsen H Salazar, Arch Pathol Lab Med 2000 124 1147 1151 10923074
32. Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas. S Serra S Salahshor M Fagih F Niakosari JM Radhi R Chetty, JOP 2007 8 296 303 17495358